Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-11-05
2010-11-02
Krass, Frederick (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07825132
ABSTRACT:
Methods of inhibiting fibroblast growth factor receptor 3 and treating various conditions mediated by fibroblast growth factor receptor 3 are provided that include administering to a subject a compound of Structure I, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I have the following structure where and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting fibroblast growth factor receptor 3 and for use in treating conditions mediated by fibroblast growth factor receptor 3 such as multiple myeloma.
REFERENCES:
patent: 3663606 (1972-05-01), Yoshikazu
patent: 4659657 (1987-04-01), Harnisch et al.
patent: 4882342 (1989-11-01), Von der Saal et al.
patent: 5073492 (1991-12-01), Chen et al.
patent: 5151360 (1992-09-01), Handa et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5414088 (1995-05-01), Von Der Saal et al.
patent: 5480883 (1996-01-01), Spada et al.
patent: 5585380 (1996-12-01), Bianco et al.
patent: 5646153 (1997-07-01), Spada et al.
patent: 5710158 (1998-01-01), Myers et al.
patent: 5763441 (1998-06-01), App et al.
patent: 5792771 (1998-08-01), App et al.
patent: 5801212 (1998-09-01), Okamoto et al.
patent: 5855866 (1999-01-01), Thorpe et al.
patent: RE36256 (1999-07-01), Spada et al.
patent: 5942385 (1999-08-01), Hirth
patent: 5981569 (1999-11-01), App et al.
patent: 6057320 (2000-05-01), Spada et al.
patent: 6111110 (2000-08-01), Brennan et al.
patent: 6137010 (2000-10-01), Joo et al.
patent: 6174912 (2001-01-01), Beck et al.
patent: 6258951 (2001-07-01), Lohmann et al.
patent: 6268391 (2001-07-01), Dickerson et al.
patent: 6303600 (2001-10-01), Cox et al.
patent: 6306874 (2001-10-01), Fraley et al.
patent: 6313138 (2001-11-01), Fraley et al.
patent: RE37650 (2002-04-01), Myers et al.
patent: 6420382 (2002-07-01), Fraley et al.
patent: 6479512 (2002-11-01), Fraley et al.
patent: 6593344 (2003-07-01), Biedermann et al.
patent: 6605617 (2003-08-01), Renhowe et al.
patent: 6756383 (2004-06-01), Renhowe et al.
patent: 6759417 (2004-07-01), Renhowe et al.
patent: 6762194 (2004-07-01), Renhowe et al.
patent: 6774237 (2004-08-01), Renhowe et al.
patent: 6774327 (2004-08-01), Wong
patent: 6800760 (2004-10-01), Renhowe et al.
patent: 7064215 (2006-06-01), Renhowe et al.
patent: 7179912 (2007-02-01), Halbrook et al.
patent: 7470709 (2008-12-01), Barsanti et al.
patent: 7598268 (2009-10-01), Renhowe et al.
patent: 2002/0103230 (2002-08-01), Renhowe et al.
patent: 2002/0107392 (2002-08-01), Renhowe et al.
patent: 2002/0165218 (2002-11-01), Halbrook et al.
patent: 2003/0028018 (2003-02-01), Renhowe et al.
patent: 2003/0087854 (2003-05-01), Monia et al.
patent: 2003/0158224 (2003-08-01), Renhowe et al.
patent: 2003/0159702 (2003-08-01), Lindell et al.
patent: 2003/0207883 (2003-11-01), Renhowe et al.
patent: 2004/0002518 (2004-01-01), Renhowe et al.
patent: 2004/0006101 (2004-01-01), Renhowe et al.
patent: 2004/0092535 (2004-05-01), Barsanti et al.
patent: 2004/0097545 (2004-05-01), Renhowe et al.
patent: 2004/0220196 (2004-11-01), Hannah et al.
patent: 2005/0054672 (2005-03-01), Renhowe et al.
patent: 2005/0137399 (2005-06-01), Cai et al.
patent: 2005/0203101 (2005-09-01), Barsanti et al.
patent: 2005/0209247 (2005-09-01), Cai et al.
patent: 2005/0256157 (2005-11-01), Gesner et al.
patent: 2005/0261307 (2005-11-01), Cai et al.
patent: 2006/0261307 (2006-11-01), Black et al.
patent: 2003290699 (2004-06-01), None
patent: 2421120 (2002-03-01), None
patent: 23463 (2003-11-01), None
patent: 2363459 (1975-06-01), None
patent: 3634066 (1988-04-01), None
patent: 19841985 (2000-03-01), None
patent: 0290153 (1988-11-01), None
patent: 0 509 717 (1992-04-01), None
patent: 0 508 800 (1992-10-01), None
patent: 0 747 771 (1996-12-01), None
patent: 0 797 376 (1997-09-01), None
patent: 0 290 153 (1998-11-01), None
patent: 1 086 705 (2001-03-01), None
patent: P104752 (2002-07-01), None
patent: 59-130284 (1984-07-01), None
patent: 63-230687 (1988-09-01), None
patent: 02-229165 (1990-09-01), None
patent: 6-9952 (1994-01-01), None
patent: 7-43896 (1995-02-01), None
patent: 8-29973 (1996-02-01), None
patent: 63-258903 (1998-10-01), None
patent: WO 91/04974 (1991-04-01), None
patent: 92/18483 (1992-10-01), None
patent: 92/20642 (1992-11-01), None
patent: WO-94/11337 (1994-05-01), None
patent: 95/15758 (1995-06-01), None
patent: 95/18801 (1995-07-01), None
patent: WO-95/18622 (1995-07-01), None
patent: 97/03069 (1997-01-01), None
patent: WO-97/21436 (1997-06-01), None
patent: 97/34876 (1997-09-01), None
patent: 97/48694 (1997-12-01), None
patent: 98/13350 (1998-04-01), None
patent: WO 98/55124 (1998-12-01), None
patent: 99/10349 (1999-03-01), None
patent: WO-99/16755 (1999-04-01), None
patent: WO-99/48868 (1999-09-01), None
patent: 99/50263 (1999-10-01), None
patent: 99/65897 (1999-12-01), None
patent: WO 00/00481 (2000-01-01), None
patent: WO-00/03990 (2000-01-01), None
patent: WO 00/03990 (2000-01-01), None
patent: WO-00/11709 (2000-03-01), None
patent: WO 00/20400 (2000-04-01), None
patent: 00/27379 (2000-05-01), None
patent: WO-00/31049 (2000-06-01), None
patent: WO-00/35492 (2000-06-01), None
patent: WO 00/58315 (2000-10-01), None
patent: WO 00/71129 (2000-11-01), None
patent: WO 00/74683 (2000-12-01), None
patent: WO 0074683 (2000-12-01), None
patent: 01/02369 (2001-01-01), None
patent: WO 01/12169 (2001-02-01), None
patent: 01/28993 (2001-04-01), None
patent: 01/29025 (2001-04-01), None
patent: WO 01/28993 (2001-04-01), None
patent: 01/52904 (2001-07-01), None
patent: WO 01/52875 (2001-07-01), None
patent: WO 01/53268 (2001-07-01), None
patent: 01/55114 (2001-08-01), None
patent: 01/62251 (2001-08-01), None
patent: 01/62252 (2001-08-01), None
patent: WO 01/74296 (2001-10-01), None
patent: 02/18383 (2002-03-01), None
patent: 02/22598 (2002-03-01), None
patent: WO 02/18383 (2002-03-01), None
patent: WO 02/22598 (2002-03-01), None
patent: 02/32861 (2002-04-01), None
patent: WO 02/26716 (2002-04-01), None
patent: WO 02/058697 (2002-08-01), None
patent: 03/004488 (2003-01-01), None
patent: WO 03/033472 (2003-04-01), None
patent: WO 03/087095 (2003-10-01), None
patent: WO 2004/018419 (2004-03-01), None
patent: 2004/030620 (2004-04-01), None
patent: 2004/031401 (2004-04-01), None
patent: WO 2004/030620 (2004-04-01), None
patent: WO 2004/043389 (2004-05-01), None
patent: 2004/063151 (2004-07-01), None
patent: WO 2004/063170 (2004-07-01), None
patent: WO-2004/073631 (2004-09-01), None
patent: WO 2004/087153 (2004-10-01), None
patent: WO-2004/103274 (2004-12-01), None
patent: WO-2005/009967 (2005-02-01), None
patent: WO-2005/037306 (2005-04-01), None
patent: WO 2005/046589 (2005-05-01), None
patent: WO 2005/046590 (2005-05-01), None
patent: WO-2005/047244 (2005-05-01), None
patent: WO 2005/053692 (2005-06-01), None
patent: WO 2005/082340 (2005-09-01), None
patent: WO 2006/081445 (2006-08-01), None
patent: WO-2006/127926 (2006-11-01), None
Cecil, Textbook of Medicine, 21stEdition (2000), Goldman & Bennett (Editors), W.B. Saunders Company (Publisher), Chapter 198, pp. 1060-1074).
U.S. Appl. No. 10/982,543, filed Nov. 5, 2004, Cai et al.
U.S. Appl. No. 10/982,757, filed Nov. 5, 2004, Cai et al.
Aprelikova, O., et al., “FLT4, a novel Class III Receptor Tyrosine Kinase in chromosome 5q33-qter1,”Cancer Res., vol. 52, pp. 746-748, Feb. 1, 1992, published by The American Association for Cancer Research, Stanford University Libraries' high Wire Press, California, United States of America.
Beals, C. R. et al., “Nuclear Export of NF-ATc Enhanced by Glycogen Synthase Kinase-3,”Science, vol. 275, pp. 1930-1933, Mar. 28, 1997.
Brownlees, J. et al., “Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3β transgenes,”NeuroReport, vol. 8, No. 15, pp. 3251-3255, Oct. 20, 1997; published by Rapid Science Publishers.
Carmeliet, P. et al. “Angiogenesis in Cancer and other Diseases,” Nature, 407, pp. 249-257 (2000).
Chan, T. A. et al., “14-3-3σ is required to
Cai Shaopei
Chou Joyce
Harwood Eric
Heise Carla C.
Machajewski Timothy D.
Foley & Lardner LLP
Krass Frederick
Novartis Vaccines and Diagnostics Inc.
Packard Benjamin
LandOfFree
Inhibition of FGFR3 and treatment of multiple myeloma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibition of FGFR3 and treatment of multiple myeloma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of FGFR3 and treatment of multiple myeloma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4195532